Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ionis reports third quarter 2025 financial results and highlights progress on key programs
October 29, 2025 7:00 AM EDT- TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 -
- DAWNZERA (donidalorsen) launch off to encouraging start -
- Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end
- Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology launch in 2026 -
- Increasing 2025 financial guidance driven by continued strength across the business
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis... More
